Природные соединения — потенциальная основа средств профилактики и терапии гепатита С

В статье обобщены результаты исследований действия природных соединений — полифенолов, полисахаридов и лектинов — из наземной и морской флоры на вирус гепатита С и течение ВГС-инфекции. Актуальность этой проблемы определяется широким распространением, бессимптомным течением острой формы с постепенным развитием неблагоприятных исходов, ограниченным доступом к эффективной этиотропной терапии в связи с высокой стоимостью, а также низкой осведомлённостью населения об этой болезни. Широкий спектр физиологического действия природных биологически активных веществ, обладающих противовирусной, иммуномодулирующей, противовоспалительной и антиоксидантной активностью, открывает будущие возможности их использования для создания фармакологических субстанций и лекарственных средств нового поколения с ассоциированной активностью для профилактики и адъювантной терапии гепатита С. Авторы обзора обращают внимание на трудности, с которыми связана разработка таких средств и некоторые возможные пути их преодоления.

1. Yang J., Qi J-L., Wang X–X. et al. The burden of hepatitis C virus in the world, China, India and the United States from 1990 to 2019. Front Public Health. 2023; 11: 1041201. doi: 10.3389/fpubh.2023.1041201.

2. Львов Д. К. Вирусный гепатит С — «ласковый убийца». Российский гастроэнтерологический журнал. 1995; 1: 4–6. [L’vov D. K. Virusnyj gepatit S — «laskovyj ubijtsa». Rossijskij Gastroenterologicheskij Zhurnal. 1995; 1: 4–6. (in Russian)]

3. Kayesh M.E.H., Kohara M., Tsukiyama-Kohara K. Toll-like receptor response to hepatitis C virus infection: a recent overview. Int J Mol Sci. 2022; 23 (10): 5475. doi: 10.3390/ijms23105475.

4. Roy A., Roy M., Gacem A. et al. Role of bioactive compounds in the treatment of hepatitis: a review. Front Pharmacol. 2022; 13: 1051751. doi: 10.3389/fphar.2022.1051751.

5. Медицинская вирусология. Д. К. Львов (ред.). М.: МИА. 2008; 655.

6. Руководство по вирусологии. Вирусы и вирусные инфекции человека и животных. Д. К. Львов (ред.). М.: МИА. 2013; 1200.

7. Дземова А.А., Ганченко Р. А., Трифонова Г. Ф., Эсауленко Э. В. Хронический гепатит С в Российской Федерации после начала программы элиминации HCV-инфекции. Гепатология и гастроэнтерология. 2020; 4 (2): 165–170.

8. Кудрявцева Е.Н., Корабельникова М. И., Богомолов П. О. и др. Структура генотипов/подтипов вируса гепатита С у взрослых пациентов с хроническим гепатитом С в Московской области. Эпидемиология и вакцинопрофилактика. 2016; 15 (2): 11–18.

9. Мескина Е.Р., Галкина Л. А., Целипанова Е. Е., Одинаева Н. Д. Каскад медицинской помощи детям с инфекций, вызванной вирусом гепатита С, в Московской области. Журнал микробиологии, эпидемиологии и иммунобиологии. 2022; 99 (5): 525–539.

10. Самохвалов Е.И., Николаева Л. И., Альховский С. В. и др. Частота встречаемости отдельных субтипов вируса гепатита с в Московском регионе. Вопросы вирусологии. 2013; 1: 36–40.

11. Keikha M., Eslami M., Yousefi B. et al. HCV genotypes and their determinative role in hepatitis C treatment. Virusdisease. 2020; 31 (3): 235–240. doi: 10.1007/s13337-020-00592-0.

12. Бюллетень Всемирной Организации здравоохранения. Гепатит С. 24.06.2022.

13. Mathur P., Kottilil S., Wilson E. Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era. J Clin Transl Hepatol. 2018; 6 (4): 1–7; doi: 10.14218/JCTH.2018.00007.

14. Дерябин П. Г. Гепатит С: современное состояние и перспективы. Вопросы вирусологии. 2012; S1: 91–103.

15. Chowdhury P., Sahuc M-E., Rouille Y. et al. Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. PLoS ONE. 2018; 13 (11): e0198226. doi: 10.1371/journal.pone.0198226.

16. Nafisi S., Roy S., Gish R. et al. Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regiments likely to be as effective as current regiments? Expert Rev Anti Infect Ther. 2016; 14 (1): 41–56. doi: 10.1586/14787210.2016.1114883.

17. Ghosh S., Sarkar T., Pati S. et al. Novel bioactive compounds from marine sources as a tool for functional food development. Front Mar Sci. 2022; Sec. Marine Biotechnology and Bioproducts. 2022; 9: 2022. doi: https://doi.org/10.3389/fmars.2022.832957.

18. Kaihatsu K., Yamabe M., Ebara Y. Antiviral mechanism of action of epigallocatechin‑3-O-gallate and its fatty acid esters. Molecules. 2018; 23 (10): 2475. doi: 10.3390/molecules23102475.

19. Niepman M., Gerresheim G. K. Hepatitis C virus translation regulation. Int J Mol Sci 2020; 21 (7): 2328. doi: 10.3390/ijms21072328.

20. Иванов А.В., Кузякин А. О., Кочетков С. Н. Молекулярная биология вируса гепатита С. Успехи биологической химии. 2005; 45: 37–86.

21. AlazardDany N., Denolly S., Boson B., Cosset F. L. Overview of HCV lyfe cycle with a special focus on current and possible future antiviral targets. Viruses. 2019; 11: 30. doi: 10.3390/v11010030.

22. Butt F., Shahid M., Hassan M. et al. A review on hepatitis C virus: role of viral and host-cellular factors in replication and existing therapeutic strategies. Egypt Liver Journal. 2022; 12: 71. doi: 10.1186/s43066-022-00232-w.

23. Tabata K., Neufeldt C. J., Bartenschlager R. Hepatitis C virus replication. Cold Spring Harb Perspect Med. 2020; 10 (3): a037093. doi: 10.1101/cshperspect.a037093.

24. Tremblai N., Young P. A., Lamarre D. HCV NS3/4A protease inhibitors and the road to effective direct-acting antiviral therapies. Hepatitis C Virus. 2016; 257–285.

25. Loutfy S.A., Elberry M. H., Farroh K. Y. et al. Antiviral activity of chitosan nanoparticles encapsulating curcumin against hepatitis C virus genotype 4a in human hepatoma cell lines. Int J Nanomedicine. 2020; 15: 2699–2715. doi: 10.2147/IJN.s241702.

26. Fatima K., Mathew S., Suhail M. et al. Docking studies of Pakistani HCV NS3 helicase: a possible antiviral drug target. PLoS ONE. 2014; 9 (9): e106339. doi: 10.1371/journal.pone.0106339.

27. Ткаченко Л.И., Малеев В. В., Сариева Д. М. Нарушение липидного обмена у больных хроническим вирусным гепатитом С. Архив внутренней медицины. 2015; 6: 50–56.

28. Cheng J.J., Li J. R., Huang M. H. et al. CD36 is a co-receptor for hepatitis C virus E1 protein attachment. Sci Rep. 2016; 6:21808. doi: 10.1038/srep21808.

29. Elgretli W., Chen T., Kronfli N., Sebastiani G. Hepatitis C virus-lipid interplay: pathogenesis and clinical impact. Biomedicines. 2023; 11 (2): 271. doi: 10.3390/biomedicines11020271.

30. Allander T., Forns X., Emerson S. U., Purcell R. H., Bukh J. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. Virology. 2000; 277 (2): 358–67. doi: 10.1006/viro.2000.0617.

31. Lapa D., Garbuglia A. R., Capobianchi M. R., Del Porto P. Hepatitis C virus genetic variability, human immune response, and genome polymorphisms: which is the interplay? Cells. 2019; 8 (4): 305. doi: 10.3390/cells8040305.

32. Ploss A., Kapoor A. Animal models of hepatitis C virus infection. Cold Spring Harb Perspect Med. 2020; 10 (5): a036970 doi: 10.1101/cshperspect. a036970.

33. Billerbeck E., Wolfisberg R., Fahnøe U., Xiao J. W., Quirk C., Luna J. M., Cullen J. M., Hartlage A. S., Chiriboga L., Ghoshal K., Lipkin W. I., Bukh J., Scheel T. K.H., Kapoor A., Rice C. M. Mouse models of acute and chronic hepacivirus infection. Science. 2017; 357 (6347): 204–208. doi: 10.1126/ science.aal1962.

34. Wakita T. Cell culture systems of HCV using JFH‑1 and other strains. Cold Spring. Harb Perspect Med. 2019; 9 (11): a036806. doi: 10.1101/cshperspect.a036806.

35. Montenegro-Landivar M.F., Tapia-Quiros P., Vecino X. et al. Polyphenols and their potential role to fight viral diseases: an review. Science of the Total Environment. 2021; 801: 149719. doi: 10.1016/j.scitotenv.2021.149719.

36. Giovinazzo G., Gerardi C., Uberti-Foppa C., Lopalco L. Can natural polyphenols help in reducing cytokine storm in COVID‑19 patients? Molecules. 2020; 25: 5888. doi: 10.3390/molecules25245888.

37. Swallah M.S., Fu H., Sun H. et al. The impact of polyphenol on general nutrient metabolism in the monogastric gastrointestinal tract. J Food Qujal. 2020; 2020: 1–12. doi: 10.1155/2020/5952834.

38. Lewandowska U., Szewczyk K., Hrabec E. et al. Overview of metabolism and bioavailability enhancement of polyphenols. J Agric Food Chem. 2013; 61 (50): 12183–12199. doi: 10.1021/jf404439b.

39. Zhang Y., Yu W., Zhang L. et al. The interaction of polyphenols and the gut microbiota in neurodegenerative diseases. Nutrients. 2022; 14 (24): 5373. doi: 103390/nu14245373.

40. Chojnacka K., Skrzypczak D., Izydorczyk G et al. Antiviral properties of polyphenols from plants. Foods. 2021; 10 (10): 2277. doi: 10.3390/ foods10102277.

41. Кролевец А. А., Мячикова Н. И., Думачева Е. В. и др. Наноструктурированные экстракты зелёного чая и их свойства. Научный результат. Технология бизнеса и сервиса. 2018; 4 (1).

42. Xu J., Xu Z., Zheng W. A review of the antiviral role of green tea catechins. Molecules. 2017; 22: 1337. doi: 10.3390/molecules22081337.

43. Chow H-H. S., Cai Y., Hakim I. A. et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenol E in healthy individuals. Clin Cancer Res. 2003; 9: 3312–3319.

44. Chen C., Qiu H., Gong J. et al. (–)-Epigallocatechin‑3‑gallate inhibits the replication cycle of hepatitis C virus. Arch Virol. 2012; 157: 1301–1312. doi: 10.1007/s00705-012-1304-0.

45. Ciesek S., Hahn T., Colpitts C. et al. The green tea polyphenol. Epigallocatechin‑3‑gallate, inhibits hepatitis C virus entry. Hepatology. 2011; 54 (6): 1947–1955; doi: 10.1002/hep.24610.

46. Calland N., Albecka A., Belouzard S. et al. (–)-Epigallocatechin‑3‑gallate is a new inhibitor of hepatitis C virus entry. Hepatology. 2012; 55: 720–729. doi: 10.1002/hep.24803.

47. Mekky R.Y., El-Ekiaby N. M., Hamza M. T. et al. Mir‑194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. J Infect. 2915; 70 (1): 78–87. doi: 10.1016/j.jinf.2014.08.013.

48. Lin Y-T., Wu Y-H., Tseng C-K. et al. Green tea phenolic epicatechins inhibit hepatitis C virus replication via cyclooxygenase‑2 and attenuate virus-induced inflammation. PLoS ONE 2013; 8 (1): e54466. doi: 10/1371/ journal.pone.0054466.

49. Левданский В.А., Левданский А. В., Кузнецов Б. Н. Выделение и изучение проантоцианидов коры кедра Pinus sibirica. Химия растительного сырья. 2022; 4: 99–105. doi: https://doi.org/10.14258/ jcprm.20220411490.

50. Calland N., Sahuc M-E., Belouzard S. et al. Polyphenols inhibit hepatitis C virus entry by a new mechanism of action. J Virol. 2015; 89 (19): 10053–10063. doi: 10.1128/JVI.01473-15.

51. Shimizu J.F., Lima C. S., Pereira C. M. et al. Flavonoids from Pterogyne nitens inhibit hepatitis C virus entry. Sci Rep. 2017; 7: 16127. doi: 10.1038/s41598-017-16336-y.

52. Rojas A., Del Campo J., Clement S. et al. Effect of Quercetin on hepatitis C virus life cycle: from viral to host targets. Sci Rep. 2016; 6: 31777. doi: 10.1038/srep31777.

53. Bachmetov L., Gal-Tanamy M., Shapira A. et al. Supression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat. 2012; 19 (2): e81–88. doi: 10.1111/j.13652893.2011.01507.x.

54. Bhattacharya D., Ansari I. H., Hamatake R. et al. Pharmacological disruption of hepatitis C NS5A protein intraand intermolecular conformations. J Gen Virol. 2014; 95 (Pt 2): 363–372. doi: 10.1099/vir.0.054569-0.

55. Lu N.T., Crespi C. M., Liu N. M. et al. A phase I dose escalation study demonstrates quercetin safety and explores potential for bioflavanoid antivirals in patients with chronic hepatitis C. Phytother Res. 2016; 30 (1): 160–168. doi: 10.1002/ptr.5518.

56. Костюк В. А. Биологическая активность куркумина и перспективы его фармакологического использования. Журнал Гродненского государственного медицинского университета. 2022; 20 (2): 144–151. doi: http://journal-grsmu.by/index.php/ois/article/view/2775.

57. Colpitts A.C.C., Schang L. M., Rachmawaty H. et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut. 2014; 63 (7): 1137–1149. doi: 10.1136/gutjnl-2012-304299.

58. Ferreira L.L.C., Abreu M. P., Costa C. B. et al. Curcumin and its analogs as a therapeutic strategy in infections caused by RNA genome viruses. Food Environ Virol. 2022; 14: 120–137. doi: 10.1007/s12560-o22-09514-3.

59. Deljoo S., Rabiee N., Rabiee M. Curcumin-hybrid nanoparticles in drug delivery system (review). Asian J Nanosci Mat. 2019; 2 (1): 66–91. doi: https://doi.org/10.26655/ajnanomat.2019.1.5.

60. Соловьева Н.Л., Сокуренко М. С., Зырянов О. А. Биодоступность куркумина и методы её повышения (обзор). Разработка и регистрация лекарственных средств. 2018; 3: 46–53.

61. Yusuf H., Novitasari E. K.D.D., Purnami N. L.W. et al. Formulation design and cell cytotoxicity of curcumin-loaded liposomal solid gels for antihepatitis C virus. Adv Pharmacol Pharm Sci. 2022: 3336837. doi: 10.1155/ 2022/3336837. eCollection 2022.

62. Wahyuni T.S., Permatasari A., Widiandani T. et al. Antiviral activities of curcuma genus against hepatitis C virus. NPC. Nat Product Communications. 2018; 13 (2): 1579–1582.

63. Naseri S., Darroudi M., Aryan E. et al. The antiviral effects of curcumin nanomicelles on the attachment and entry 0f hepatitis C virus. Iran J Virol. 2017; 11: 29–35.

64. Blaising J., Levy P. L., Gondeau C. et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol. 2013; 15 (11): 1866–1882. doi: 10.1111/cmi.12155.

65. Esser-Nobis K., Romero-Brev I., Ganten T. M. et al. Analyssis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology. 2013; 57 (3): 953–963. doi: 10.1002/hep.26260.

66. DebRoy S., Hiraga N., Imamura M. et al. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J. Viral Hepat. 2016; 23: 708–717; doi: 10.1111/jvh.12551.

67. Казюлин А.Н., Шестаков В. А., Гончаренко Ю. А. и др. Препараты стандартизированного силимарина. Механизмы действия и перспективы клинического применения. Экспериментальная и клиническая гастроэнтерология. 2018; 7: 73–85.

68. Liu C-H., Jassey A., Hsu H-Y., Lin L-T. Antiviral activities of silymarin and derivatives. Molecules. 2019; 24 (8): 1552. doi: 10.3390/molecules24081552.

69. Wagoner J., Negash A., Kane O. J. et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010; 51 (6): 1912–1921. doi: 10.1002/hep.23587.

70. Ahmed S., Ullah N., Jalil N. A.C. et al. Effect of sylimarin as an adjunct therapy in combination with sofosbuvir and ribavirin in hepatitis C patients: a miniature clinical trial. Oxid Med Cell Longev. 2022; 2022: 9199190. doi: 10.1155/2022/9199190.

71. Lozano-Sepulveda S., Rincon-Sanches A. R., Rivas-Estilla A. M. Antioxidants benefits in hepatitis C infection in the new DAAs era. Ann Hepatol. 2019; 18 (3): 410–415. doi: 10.1016/j.aohep.2019.04.004.

72. Gheda S.F., El-Adawi H. I., El-Deeb N. M. Antiviral profile of brown and red seaweed polysaccharides against hepatitis C virus. Iran J Pharm Res. 2016; 15 (3): 483–491.

73. Hamed I., Ozogul F., Ozogul Y., Regenstein J. M. Marine bioactive compounds and their health benefits: a review. Comprehensive reviews in Food Science and Food Safety. 2015; 14 (4): 446–465. doi: 10.1111/1541-4337.12136.

74. Besednova N.N., Andryukov B. G., Zaporozhets T. S. et al. Antiviral effects of polyphenols from varine algae. Biomedicines. 2021; 9 (2): 200. doi: 10.3390/biomedicines9020200.

75. Heffernan N., Smyth T. J., Soler-Villa A. et al. Phenolic content and antioxidant activity of fractions obtained from selected Irish microalgae species (Laminaria digitate, Fucus serratus, Gracillaria gracilis and Codium fragile). J Appl Phycol. 2014; 27: 519–530; doi: 10.1007/s10811014-0291-9.

76. Имбс Т.И., Звягинцева Т. Н. Флоротаннины — полифенольные метаболиты бурых водорослей. Биология моря. 2018; 44: 217–227. doi: https://doi.org/10.1134/SO134347518040010.

77. Li A-N., Li S., Zhang Y. J. et al. Resources and biological activities of natural polyphenols. Nutrients. 2014; 6: 6020–6047. doi: 10.3390/nu6126020.

78. Cotas J., Leandro A, Monteiro P. et al. Seaweed phenolics: from extraction to application. Mar Drugs.2020; 18 (8): 384. doi: 10.3390/md18080384.

79. Chen K-J., Tseng C-K., Chang F-R. et al. Aqueous extract of the edible Gracillaria tenustipitata inhibits hepatitis C viral replication via cyclooxygenase‑2 suppression and reduces virus-induced inflammation. PLoS ONE. 2013; 8 (2): e57704; doi: 10.1371/journal.pone.0057704.

80. Evans H., Plummer C., Luck M. et al. Anti-viral composition. Patent WO 2020/115489 A1. 11.06.2020.

81. Li S., Tan H. Y., Wang N. et al. The potential and action mechanism of polyphenols in the treatment of liver diseases. Therapeutic Potential of Natural Antioxidants. 2018; article ID 8394818. doi: 10.1155/2018/8394818.

82. Fitton J.H., Stringer D. N., Park A. Y., Karpiniec S. S. Therapies from fucoidan: new developments. Mar Drugs. 2019; 17 (10): 571. doi: 10.3390/ md17100571.

83. Wassie T., Niu K., Xie C. et al. Extraction techniques, biological activities and health benefits of marine algae Enteromorpha prolifera polysaccharide. Fronti Nutr. 2021; 8: 747928. doi: 10.3389/fnut.2021.747928.

84. Zheng L–X., Liu Y., Tang S. et al. Preparation methods, biological activities, and potential applications of marine algae oligosaccharides: a review. Food Science and Human Wellness. 2023; 12 (2): 359–370. doi: 10.1016/j.fshw.2022.07.038.

85. Martins A., Alves C., Silva J. et al. Sulfated polysaccharides from macroalgae — a simple roadmap for chemical characterization. Polymers. 2023; 15 (2): 399. doi: 10.3390/polym15020399.

86. Shi F., Liu Z., Liu Y. et al. Comparison of physicochemical characteristics and macrophage immunostimulatory activities of polysaccharides from Chlamys farreri. Mar Drugs. 2020; 18 (8): 429. doi: 10.3390/md18080429.

87. Claus-Desbonnet H., Nikly E., Nalbantova V. et al. Polysaccharides and their derivatives as potential antiviral molecules. Viruses. 2022; 14 (2): 426. doi: 10.3390/v14020426.

88. Panggabean J.A., Adiguna S. P., Rahmawati S. et al. Antiviral activities of algal-based sulfated polysaccharides. Molecules. 2022; 27 (4): 1178. doi: 10.3390/molecules27041178.

89. Bai R.G., Tuvikene R. Potential antiviral properties of industrially important marine algal polysaccharides and their significance in fighting a future viral pandemic. Viruses. 2021; 13 (9): 1817. doi: 10.3390/v13091817.

90. Mori N., Nakasone K., Tomomori K., Ishikawa C. Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection. World J Gastroenterol. 2012; 18 (18): 2225–2230. doi: 10.3748/wjg.v18.i18.2225.

91. Филонова Н.В., Запорожец Т. С., Ермолицкая С. А. и др. Влияние фукоидана из Fucus evanescens на показатели цитокинового статуса у пациентов с хроническим гепатитом С. Цитокины и воспаление. 2011; 10 (4): 105–110.

92. Ueno M., Nogawa M., Siddiqui R. et al. Acidic polysaccharides isolated from marine algae inhibit the early step of viral infection. Int J Biol Macromol. 2019; 124: 282–290. doi: 10.1016/j.ijbiomac.2018.11.152.

93. Nabi-Afjadi M., Heydari M., Zalpoor H. et al. Lectins and lectibodies: potential promising antiviral agents. Cell Mol Biol Lett. 2022; 27: 37. doi: 10.1186/s11658-022-00338-4.

94. Черников О.В., Молчанова В. И., Чикаловец И. В. и др. Лектины морских гидробионтов (обзор). Биохимия. 2013; 78 (7): 977–989.

95. Cheung R.C.F., Wong J. H., Pan W. et al. Marine lectins and their medicinal application. Appl Microbiol Biotechnol. 2015; 99: 3755–3773. doi: 10.1007/ s00253-o15-6518.

96. Mitchell C.A., Ramessar K., Keefe B. R. Antiviral lectins: selective inhibitors of viral entry. Antiviral Res. 2017; 142: 37–54. doi: 10.1016/j.antiviral. 2017.03.007.

97. Singh R.S., Thakur S. R., Bansal P. Algal lectins biomolecules for biomedical research. Crit Rev Microbiol. 2015; 41 (1): 77–88. doi: 10.3109/1040841X. 2013.798780.

98. Mazur-Marzec H., Ceglowska M., Konkel R., Pyrc K. Antiviral cyanometabolites — a review. Biomolecules. 2021; 11 (3): 474. doi: 10.3390/biom11030474.

99. Romero J.A.F., Paglini M. G., Priano C. et al. Algal and cyanobacterial lectins and their antimicrobial properties. Mar Drugs. 2021; 19 (12): 687. doi: 10.3390/md19120687.

100. Lusvarghi S., Bewley C. A. Griffitsin: an antiviral lectin with outstanding therapeutic potential. Viruses. 2016; 8 (10): 296. doi: 10.3390/v8100296.

101. Meuleman P., Albecka A., Belouzard S. et al. Griffitsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother. 2011; 55 (11): doi: 10.1128/AAC.00633-11.

102. Helle F., Wychowski C., Vu-Dac N. et al. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem. 2006; 281: 25177–25183. doi: 10.1074/jbc.M602431200.

103. Takebe Y., Saucedo C. J., Lund G. et al. Antiviral lectins from red and blue-grin algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS ONE. 2013; 8 (5): e64449. doi: 10.1371/journal.pone0064449.

104. Min Y-Q., Duan X–C., Zhou Y-D. et al. Effects of microvirin monomers and oligomers on hepatitis C virus. Biosci Rep. 2017; 37: BSR20170015. doi: 10.1042/BSR20170015.

105. Izquierdo L., Oliveira C., Fournier C. et al. Hepatitis C virus resistance to carbohydrate-binding agents. PLoS ONE. 2016; 11 (2): e0149064/ doi: 10.1371/journal.pone.1149064.

106. Lavie M., H., Hanoulle X., Dubuisson J. Glycan shielding and modulation of hepatitis C virus neutralizing antibodies. Front Immunol. 2018; 9:910; doi: 10.3389/fimmu.2018.00910.

107. Dent M., Hamorsky K., Dubuisson J. et al. Safety and efficacy of avarenFc lectibody targeting HCV high-mannose glycans in a human liver chimeric mouse model. Cell Mol Gastroenterol Hepatol. 2020; 11: 185–198. doi: 10.1016/j.jcmgh.2020.08.009.

108. LeBlanc E.V., Kim Y., Capicciotti C. J., Colpitts C. C. Hepatitis C virus glycan-dependent interactions and the potential for novel preventative strategies. Pathogens. 2021; 10 (6): 685. doi: 10.3390/pathogens10060685.

109. Carola O. Effect of avaren-Fc lectibody on HCV in a human liver chimeric mouse model. J Drug Abuse. 2022; 8: 117. https://www.primescholars.com/drug-abuse.html.